| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Veru Inc (NASDAQ: VERU)
VERU Technical Analysis
5
| As on 9th Jun 2023 VERU SHARE Price closed @ 1.31 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 10.32 & Strong Sell for SHORT-TERM with Stoploss of 5.64 we also expect STOCK to react on Following IMPORTANT LEVELS. |
VERUSHARE Price
| Open | 1.32 | Change | Price | % |
| High | 1.34 | 1 Day | 0.00 | 0.00 |
| Low | 1.24 | 1 Week | 0.32 | 32.32 |
| Close | 1.31 | 1 Month | 0.04 | 3.15 |
| Volume | 1211195 | 1 Year | -5.03 | -79.34 |
| 52 Week High 23.78 | 52 Week Low 0.98 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| VERU Daily Charts |
VERU Intraday Charts |
Whats New @ Bazaartrend |
VERU Free Analysis |
|
|
VERU Important Levels Intraday
| RESISTANCE | 1.50 |
| RESISTANCE | 1.44 |
| RESISTANCE | 1.40 |
| RESISTANCE | 1.36 |
| SUPPORT | 1.26 |
| SUPPORT | 1.22 |
| SUPPORT | 1.18 |
| SUPPORT | 1.12 |
VERU Forecast April 2024
| 4th UP Forecast | 5.72 |
| 3rd UP Forecast | 4.31 |
| 2nd UP Forecast | 3.43 |
| 1st UP Forecast | 2.56 |
| 1st DOWN Forecast | 0.06 |
| 2nd DOWN Forecast | -0.81 |
| 3rd DOWN Forecast | -1.69 |
| 4th DOWN Forecast | -3.1 |
VERU Weekly Forecast
| 4th UP Forecast | 2.39 |
| 3rd UP Forecast | 2.04 |
| 2nd UP Forecast | 1.83 |
| 1st UP Forecast | 1.62 |
| 1st DOWN Forecast | 1.00 |
| 2nd DOWN Forecast | 0.79 |
| 3rd DOWN Forecast | 0.58 |
| 4th DOWN Forecast | 0.23 |
VERU Forecast2024
| 4th UP Forecast | 46.83 |
| 3rd UP Forecast | 32.23 |
| 2nd UP Forecast | 23.21 |
| 1st UP Forecast | 14.18 |
| 1st DOWN Forecast | -11.56 |
| 2nd DOWN Forecast | -20.59 |
| 3rd DOWN Forecast | -29.61 |
| 4th DOWN Forecast | -44.21 |
Veru Inc ( NASDAQ USA Symbol : VERU )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VERU Business Profile
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida. Address: 48 NW 25th Street, Miami, FL, United States, 33127
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service